ArticleJournal of neuroinflammation2026
Phosphorylated TYK2 orchestrates the pathogenic program of CD4 + T cells in the development of CNS autoimmunity.
Article in Journal of neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exosome Biology at the Interface of Neurodegeneration and Therapeutic Innovation.Molecular neurobiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe imbalance between pathogenic Th1/Th17 cells and regulatory T cells (Tregs) is a central mechanism in central nervous system (CNS) autoimmune diseases, including autoimmune uveitis (AU) and multiple sclerosis. Tyrosine kinase 2 (TYK2) mediates signaling downstream of multiple cytokines implicated in CD4 + T cell differentiation, yet its subset-specific activation and therapeutic potential in CNS autoimmunity remain unclear. Here, we investigated the subset-specific activation of TYK2 and evaluated the therapeutic potential of selective TYK2 inhibition in CNS autoimmune diseases.
methodsTYK2 phosphorylation was examined in CD4 + T cell subsets from AU patients and from experimental autoimmune uveitis (EAU) and encephalomyelitis (EAE) models. The therapeutic effects and mechanisms of a selective TYK2 inhibitor were assessed using flow cytometry, single-cell RNA sequencing, adoptive transfer, in vitro cellular assays, and ex vivo stimulation of patient peripheral blood mononuclear cells.
resultsTYK2 phosphorylation was preferentially activated in Th1 and Th17 cells compared with Tregs in both patients and disease models. TYK2 inhibition significantly reduced clinical and histopathological scores in EAU and EAE, suppressing Th1/Th17 differentiation and production of IFN-γ and IL-17A, while Treg proportion and function remained intact. Mechanistically, IFN-α/β, IL-12, and IL-23-but not IL-2-induced TYK2 phosphorylation in CD4 + T cells. Accordingly, TYK2 blockade selectively inhibited STAT1/2/3/4 activation downstream of these cytokines without affecting IL-2-induced STAT5 phosphorylation in Tregs. These lineage-selective effects were confirmed in peripheral blood mononuclear cells from AU patients.
conclusionTYK2 acts as a lineage-selective therapeutic target in CNS autoimmunity. Its inhibition suppresses pathogenic Th1/Th17 responses while preserving Treg proportion and function by targeting cytokine-specific signaling pathways, thereby rebalancing the effector-regulatory immune axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.